We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$186M
AUM Growth
+$24.6M
Cap. Flow
+$12.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
43.12%
Holding
83
New
10
Increased
18
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$4.09M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$2.82M
4
SAGE
Sage Therapeutics
SAGE
+$2.79M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.06M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.85M
2
QURE icon
uniQure
QURE
+$1.68M
3
PODD icon
Insulet
PODD
+$1.64M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$1.48M
5
ONC
BeOne Medicines Ltd
ONC
+$961K

Sector Composition

Rank Sector Weight
1 Healthcare 82.51%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KA
51
DELISTED
Kineta, Inc. Common Stock
KA
$685K 0.37%
+839
New +$322K
CYPH
52
Cypherpunk Technologies Inc
CYPH
$65.4M
$676K 0.36%
+10,833
New +$653K
LCTX icon
53
Lineage Cell Therapeutics
LCTX
$267M
$591K 0.32%
+314,325
New +$686K
LMNX
54
DELISTED
Luminex Corp
LMNX
$493K 0.27%
25,000
– –
MASI
55
DELISTED
Masimo
MASI
$424K 0.23%
5,000
– –
CASC
56
DELISTED
Cascadian Therapeutics, Inc.
CASC
$395K 0.21%
106,810
-10,500
-9% -$43K
BLUE
57
DELISTED
bluebird bio
BLUE
$356K 0.19%
154
-193
-56% -$392K
NTUS
58
DELISTED
Natus Medical Inc
NTUS
$302K 0.16%
7,900
– –
NEOS
59
DELISTED
Neos Therapeutics, Inc
NEOS
$281K 0.15%
27,500
– –
DCPH
60
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$218K 0.12%
9,619
-10,381
-52% -$203K
PDSB icon
61
PDS Biotechnology
PDSB
$38.6M
$182K 0.1%
970
– –
RDHL
62
Redhill Biopharma
RDHL
$4.44M
$180K 0.1%
+35
New +$236K
BLCM
63
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$168K 0.09%
2,000
– –
OBSV
64
DELISTED
ObsEva SA Ordinary Shares
OBSV
$139K 0.07%
14,225
-71,775
-83% -$729K
SPRO icon
65
Spero Therapeutics
SPRO
$69.5M
$59K 0.03%
+5,000
New +$61.4K
ATNM icon
66
Actinium Pharmaceuticals
ATNM
$27.2M
– –
-11,100
Closed -$192K
CTMX icon
67
CytomX Therapeutics
CTMX
$701M
– –
-5,900
Closed -$107K
QURE icon
68
uniQure
QURE
$2.52B
– –
-175,307
Closed -$1.68M
SLS icon
69
SELLAS Life Sciences
SLS
$1.98B
– –
-31
Closed -$16K
DMK
70
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-349
Closed -$127K
ISEE
71
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-50,000
Closed -$141K
FSTX
72
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-1,627
Closed -$110K
SRRA
73
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,100
Closed -$68K
KDMN
74
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-125,000
Closed -$419K
NDRM
75
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-37,938
Closed -$1.48M
1 2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, DAFNA Capital Management held 83 positions worth $186M, up 15% from $161M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management deployed $12.5M of net new capital in Q4 2017, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.85M trimmed.

  • DAFNA Capital Management's largest Q4 2017 buy was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.
  • DAFNA Capital Management added most to Zogenix, Inc. in Q4 2017, an estimated $3.14M increase.
  • DAFNA Capital Management's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $1.85M.
  • DAFNA Capital Management fully exited uniQure in Q4 2017, selling an estimated $1.68M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $186M portfolio in Q4 2017.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q4 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $186M.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.